Patients on GLP-1 RAs exhibited a 195% higher risk of major depression, a 108% increased risk for anxiety, and a 106% elevated risk for suicidal behavior.
For those suffering, here's a 7 year study that was recently published.
Data Source: TriNetX database (2015–2023), including 11.6 million patients with obesity.
Participants:
GLP-1 RA Users: 162,257 people.
Non-GLP-1 RA Users: 9.1 million people.
Patients were matched by age, sex, race, and health conditions to ensure fair comparisons.
GLP-1 RA users were found to have a 98% higher likelihood of developing psychiatric disorders compared to non-users, with depression showing a 195% increased risk, anxiety a 108% higher risk, and suicidal behavior a 106% elevated risk. These risks varied across demographics, with women being more affected than men, particularly for depression. Younger adults aged 18–49 faced a greater likelihood of suicidal thoughts or attempts, while Black patients exhibited the highest risk for anxiety among racial groups.